Short-Chain HDAC Inhibitors Differentially Affect Vertebrate Development and Neuronal Chromatin
ACS Medicinal Chemistry Letters2010Vol. 2(1), pp. 39–42
Citations Over TimeTop 10% of 2010 papers
Daniel M. Fass, Rishita Shah, Balaram Ghosh, Krista M. Hennig, Stephanie Norton, Wen‐Ning Zhao, Surya A. Reis, Peter S. Klein, Ralph Mazitschek, Rebecca L. Maglathlin, Timothy A. Lewis, Stephen J. Haggarty
Abstract
Carboxylic acids with known central nervous system and histone deacetylase (HDAC) inhibitory activities were converted to hydroxamic acids and tested using a suite of in vitro biochemical assays with recombinant HDAC isoforms, cell based assays in human cervical carcinoma Hela cells and primary cultures from mouse forebrain, and a whole animal (Xenopus laevis) developmental assay. Relative to the parent carboxylic acids, two of these analogs exhibited enhanced potency, and one analog showed altered HDAC isoform selectivity and in vivo activity in the Xenopus assay. We discuss potential uses of these novel hydroxamic acids in studies aimed at determining the utility of HDAC inhibitors as memory enhancers and mood stabilizers.
Related Papers
- → Self-Regulation of Affect–Health Behavior Relations(2018)7 cited
- → Assessing the Initial Pleasantness for Fading Affect, Fixed Affect, Flourishing Affect, and Flexible Affect Events(2016)8 cited
- → Fish fossil unfolds clues to vertebrate brain evolution(2023)1 cited
- Interaction of platelets with invertebrate and lower vertebrate collagens.(1993)
- Advances in vertebrate origin and evolvement (PlatesVIII,IX)(2004)